<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01020565</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-053</org_study_id>
    <nct_id>NCT01020565</nct_id>
  </id_info>
  <brief_title>A Study in Japan of the Safety and Antiviral Activity With Chronic Hepatitis B Infection</brief_title>
  <official_title>A Phase II Study in Japan of the Safety and Antiviral Activity of Entecavir (BMS-200475) in Adults With Chronic Hepatitis B Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to demonstrate that entecavir has antiviral activity with
      undetectable at Week 48, and to assess the safety and the pharmacokinetic in Japanese
      patients given entecavir at each dose of 0.1 and 0.5 mg for 52 weeks
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of clinical adverse events and discontinuations due to adverse events of entecavir at doses of 0.5 and 1 mg</measure>
    <time_frame>Week 52 (end of dosing) plus 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities of entecavir at doses of 0.5 and 1 mg for 52 weeks</measure>
    <time_frame>Week 52 (end of dosing) plus 5 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with reduction in HBV DNA by ≥2 log10 or to undetectable level (&lt;400 copies/mL) by PCR assay</measure>
    <time_frame>Week 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in log10 HBV DNA measured by PCR assay for each entecavir dose (0.5 and 1 mg) at Week 48</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve undetectable HBV DNA (&lt;400 copies/mL) by PCR assay at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects HBeAg-positive at baseline who have loss of HBeAg from serum at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects HBeAg-positive at baseline who achieve seroconversion (loss of HBeAg and appearance of HBeAb) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with abnormal ALT at baseline who achieve normalization of serum ALT (&lt;1.25 x ULN) at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects HBeAg-positive at baseline who have Complete Response [undetectable HBV DNA levels by PCR assay, negative for HBeAg and normal serum ALT] at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects HBeAg-negative at baseline who have Complete Response [undetectable HBV DNA levels by PCR assay, remain negative for HBeAg and normal serum ALT] at Week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve Complete Response, and remain Complete response for 24 weeks after stopping drug</measure>
    <time_frame>Week 72</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects w/ histological improvement in liver (improvement in necroinflammatory score (≥2 points decrease, Knodell HAI3 score) &amp; no worsening of fibrosis (≥1 point increase, Knodell fibrosis score) at Wk 48 liver biopsy compared to baseline</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver histology as assessed by the New Inuyama Classification for histological assessment of chronic hepatitis</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between HBV isolates (genotypes A,B,C, etc.) at baseline and antiviral activity</measure>
    <time_frame>Week 48, or at end of dosing (up to Week 52)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of resistance mutations of HBV isolates in subjects who have a rise in HBV DNA (by ≥1 log above the nadir for that subject) while on study drug.</measure>
    <time_frame>Week 48, or at end of dosing (up to Week 52)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutation of HBV DNA polymerase at Week 48 from baseline</measure>
    <time_frame>Baseline, Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentrations of entecavir at selected time points during the treatment period</measure>
    <time_frame>pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Population pharmacokinetic assessment of entecavir developed from concentration-time data obtained from healthy subjects</measure>
    <time_frame>pre-dosing, Week 2 or 4, Week 12, Week 24 and Week 36</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entecavir (0.1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir (0.5 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks</description>
    <arm_group_label>Entecavir (0.1 mg)</arm_group_label>
    <arm_group_label>Entecavir (0.5 mg)</arm_group_label>
    <other_name>Baraclude</other_name>
    <other_name>BMS-200475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documentation of chronic hepatitis B infection by ALL of the following:

               1. Positive for HBsAg OR, negative for IgM core antibody and confirmation of chronic
                  hepatitis B on liver biopsy

               2. Positive for HBeAg OR negative for HBeAg

               3. Documented HBV Viremia on 2 or more occasions and at screening visit: Viremia on
                  sample drawn AND HBV DNA of ≥ 10*5* copies/mL by PCR assay at the screening visit

          -  ALT in the range of 1.3 to 10 x ULN
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <reference>
    <citation>Kobashi H, Takaguchi K, Ikeda H, Yokosuka O, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Sakaguchi K, Shiratori Y. Efficacy and safety of entecavir in nucleoside-naive, chronic hepatitis B patients: phase II clinical study in Japan. J Gastroenterol Hepatol. 2009 Feb;24(2):255-61. doi: 10.1111/j.1440-1746.2008.05593.x.</citation>
    <PMID>19215336</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2009</study_first_posted>
  <disposition_first_submitted>January 29, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 29, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 2, 2010</disposition_first_posted>
  <last_update_submitted>August 4, 2010</last_update_submitted>
  <last_update_submitted_qc>August 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

